2356 Phase I dose-escalation study of nintedanib in Japanese patients with advanced hepatocellular carcinoma (HCC) and mild or moderate liver impairment. (September 2015) - Ikeda, M.; Otsuka, T.; Ueno, H.; Mitsunaga, S.; Sugimoto, R.; Muro, K.; Saito, I.; Sasaki, T.; Inoue, K.; Loembe, A.B.; Okusaka, T.